Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMar 13, 2025
DataAggregated Company Financials
Companies567
- 7D-1.0%
- 3M-2.6%
- 1Y-6.9%
- YTD1.3%
Last week, the Biotech industry hasn't moved much but Protagonist Therapeutics is up 50% in that time. Unfortunately though, the industry is down 6.9% over the past 12 months. As for the next few years, earnings are expected to grow by 27% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 13 Mar 2025 | US$834.6b | US$118.7b | -US$37,659,545,163.68 | 18.4x | -22.2x | 7x |
| Sat, 08 Feb 2025 | US$857.1b | US$117.3b | -US$30,948,989,158.04 | 17.2x | -27.7x | 7.3x |
| Mon, 06 Jan 2025 | US$980.2b | US$149.6b | -US$26,354,792,434.12 | 17x | -37.2x | 6.6x |
| Wed, 04 Dec 2024 | US$1.0t | US$149.9b | -US$26,584,927,055.40 | 16.5x | -39.1x | 6.9x |
| Fri, 01 Nov 2024 | US$1.1t | US$147.3b | -US$30,454,139,694.27 | 17.1x | -34.7x | 7.2x |
| Sun, 29 Sep 2024 | US$893.6b | US$113.2b | -US$36,006,680,210.71 | 21.3x | -24.8x | 7.9x |
| Tue, 27 Aug 2024 | US$909.0b | US$113.1b | -US$35,851,266,005.46 | 23.3x | -25.4x | 8x |
| Thu, 25 Jul 2024 | US$1.2t | US$164.5b | -US$28,090,976,401.93 | 28.2x | -43x | 7.3x |
| Sat, 22 Jun 2024 | US$1.1t | US$164.4b | -US$27,943,646,272.00 | 28.1x | -41.1x | 7x |
| Mon, 20 May 2024 | US$1.1t | US$164.6b | -US$26,835,738,666.64 | 23.9x | -42.8x | 7x |
| Wed, 17 Apr 2024 | US$1.1t | US$164.2b | -US$23,402,696,044.05 | 20.5x | -46.3x | 6.6x |
| Fri, 15 Mar 2024 | US$1.2t | US$167.4b | -US$22,100,849,384.54 | 16.3x | -54.1x | 7.1x |
| Sun, 11 Feb 2024 | US$1.2t | US$169.3b | -US$26,263,046,791.87 | 19.8x | -44.2x | 6.9x |
| Tue, 09 Jan 2024 | US$1.4t | US$204.8b | -US$22,499,844,981.00 | 20.8x | -63.1x | 6.9x |
| Thu, 07 Dec 2023 | US$1.3t | US$204.6b | -US$22,056,080,007.00 | 19.4x | -58.1x | 6.3x |
| Sat, 04 Nov 2023 | US$1.2t | US$206.7b | -US$20,531,174,316.00 | 18.8x | -60.4x | 6x |
| Mon, 02 Oct 2023 | US$1.3t | US$207.4b | -US$13,122,605,528.00 | 17.1x | -95.8x | 6.1x |
| Wed, 30 Aug 2023 | US$1.3t | US$207.6b | -US$12,432,896,963.00 | 17.8x | -103.8x | 6.2x |
| Fri, 28 Jul 2023 | US$1.1t | US$186.8b | -US$16,232,166,533.00 | 14.3x | -69.6x | 6x |
| Sun, 25 Jun 2023 | US$1.1t | US$186.2b | -US$16,162,116,001.00 | 13.6x | -70.3x | 6.1x |
| Tue, 23 May 2023 | US$1.2t | US$186.0b | -US$15,902,975,009.00 | 13.3x | -72.9x | 6.2x |
| Thu, 20 Apr 2023 | US$1.2t | US$198.4b | -US$3,264,741,817.00 | 13.6x | -362.5x | 6x |
| Sat, 18 Mar 2023 | US$1.1t | US$199.2b | -US$3,900,694,523.00 | 13.2x | -286.4x | 5.6x |
| Mon, 13 Feb 2023 | US$1.2t | US$202.7b | -US$211,129,546.00 | 16.4x | -5476.8x | 5.7x |
| Wed, 11 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.1x | 695.4x | 5.7x |
| Fri, 09 Dec 2022 | US$1.2t | US$202.7b | US$1.4b | 14.9x | 819.9x | 5.8x |
| Sun, 06 Nov 2022 | US$1.1t | US$204.6b | US$3.6b | 14.2x | 299.5x | 5.3x |
| Tue, 04 Oct 2022 | US$1.0t | US$206.2b | US$5.5b | 14.6x | 189.3x | 5x |
| Thu, 01 Sep 2022 | US$1.0t | US$206.4b | US$7.3b | 14.1x | 140x | 5x |
| Sat, 30 Jul 2022 | US$1.1t | US$212.0b | US$11.3b | 15.6x | 93.2x | 5x |
| Mon, 27 Jun 2022 | US$1.1t | US$212.4b | US$11.1b | 15.4x | 95.1x | 4.9x |
| Wed, 25 May 2022 | US$992.4b | US$212.8b | US$11.1b | 15.7x | 89.2x | 4.7x |
| Fri, 22 Apr 2022 | US$1.2t | US$226.7b | US$14.8b | 18x | 82.8x | 5.4x |
| Sun, 20 Mar 2022 | US$1.3t | US$222.3b | US$10.5b | 19.8x | 123.5x | 5.8x |
Price to Earnings Ratio
123.5x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 19% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -4.41% | |
| Healthcare | -3.83% | |
| Biotech | -0.96% | |
| Biotech | -0.96% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | US$57.65 | 49.9% +US$1.2b | 90.9% | PE12.9x | |
| VRTX Vertex Pharmaceuticals | US$495.42 | 0.8% +US$970.7m | 19.9% | PS11.5x | |
| ABBV AbbVie | US$212.06 | 0.2% +US$918.0m | 17.9% | PE88.3x | |
| LEGN Legend Biotech | US$38.24 | 10.2% +US$649.4m | -43.8% | PS11.2x | |
| APGE Apogee Therapeutics | US$38.53 | 22.6% +US$412.4m | -44.8% | PB3.1x |